DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
-
UBP 302 (HB0627)
Description:Potent, selective GluK1 subunit selective kainate receptor antagonist
Purity:>98%
-
UBP 310 (HB0628)
Description:Potent, selective GluK1 / GluK3 subunit selective kainate receptor antagonist
Purity:>98%
-
Urapidil hydrochloride (HB1693)
Description:Selective 5-HT1A agonist. α1-adrenoceptor antagonist
Purity:>99%
-
-
-
WAY 100635 maleate (HB1790)
Description:Potent 5-HT1A receptor antagonist. D4 receptor agonist.
Purity:>99%
-
-
YM 298198 hydrochloride (HB0664)
Description:Potent, selective, non-competitive mGlu1 antagonist
Purity:>99%
-
Zacopride hydrochloride (HB1694)
Description:Potent 5-HT3 antagonist and 5-HT4 agonist. Also selective IK1 channel agonist.
Purity:>99%
